Diligence memo · auto-generated · as of July 2, 2026
Allied BioScience, Inc.
Allied BioScience, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Allied BioScience, Inc. operates in Biotechnology, based in FARMERS BRANCH.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Allied BioScience, Inc. has raised $22M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.5M on 2017-07-01.
Most recent recorded round closed around 2021-10-01.
Valuation (modeled)modeled
Provath models Allied BioScience, Inc. at approximately $74M (range $4.1M–$302M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.41× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 4.7 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.4× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 69% of Biotechnology peers (4293 compared).
Modeled value ranks above 53% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
20 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.